Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells.

By E. Small, Paige Fratesi, D. Reese, G. Strang, R. Laus, M. Peshwa, F. Valone. Journal of Clinical Oncology, 2000

637 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Technical (1960, neutral): “Perception , responsible for standardizing heterogeneous input data from Any External Device.”
Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. (2006, methodology): “Data from phase I and II trials suggest that quiescent APCs cultured with PA2024 undergo activation and upregulation of costimulatory molecules.(5) From the University of California San”
PROVENGE (Sipuleucel-T) in Prostate Cancer: The First FDA-Approved Therapeutic Cancer Vaccine (2011, background): “Early-phase trials Sequential phase I and II studies evaluated the safety of the PAP vaccine and the ability to circumvent immune tolerance to PAP (9, 10).”
Integrated data from 2 randomized, double‐blind, placebo‐controlled, phase 3 trials of active cellular immunotherapy with sipuleucel‐T in advanced prostate cancer (2009, background): “We have previously demonstrated that maximal immune response in some patients may not occur until 12 weeks or longer after initiation of therapy.(12) Progression as defined in this study may therefore have reflected in part what was in progress at the time of enrollment, and not necessarily progress”